EVAX•globenewswire•
Evaxion expands AI-Immunology™ platform into autoimmune diseases
Summary
COPENHAGEN, Denmark, January 13, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will expand the use of its proprietary AI-Immunology™ platform to also discover and develop new treatments for autoimmune diseases. Thus, Evaxion will in the future work within cancers, infectious and autoimmune diseases as its core disease areas.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 13, 2026 by globenewswire